
-
Vincerx Pharma: Finding Strength In Symbiosis8/1/2023
Ahmed Hamdy and Raquel Izumi are putting the lessons, hard knocks, and experiential wisdom they have gained over a decade in biotech to work at Vincerx.
-
I-MAK's Quest To Trim The Biopharmaceutical Patent Thicket7/3/2023
I-MAK, a nonprofit focused on reforming the drug patent system, is bringing patients into the patent system to advocate against abuses that keep affordable drugs out of reach.
-
Civica Takes On Insulin Market, Opens Manufacturing Facility7/3/2023
With a new manufacturing plant opening in Virgina, Civica is poised to move into new product areas, including affordable insulin.
-
More Than A Seat At The Table7/3/2023
Bringing different perspectives together is important when debating industry policies, but the middle ground can still be allusive.
-
From Biggest Pharma To Rare Disease Start-Up6/1/2023
Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech.
-
More Transparency, To A Point6/1/2023
New salary transparency laws are being enacted by a growing number of states, and more transparency is needed to address existing inequities. Is it possible to be too transparent?
-
Leading Aulos Bioscience's “Triumvirate” Model6/1/2023
Aulos Bioscience hopes to leverage its unique business model, engineered by a VC firm and an Israeli biotech, to develop better treatments for solid tumors.
-
Fortress Biotech's Network Flex Business Model5/1/2023
Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates.
-
The Skin Is The Game: New Ways To Play In Dermatology5/1/2023
As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.